Alnylam Pharmaceuticals
ALNY
#648
Rank
NZ$68.96 B
Marketcap
NZ$516.51
Share price
-0.61%
Change (1 day)
-3.07%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.72. In 2025 the company made an earnings per share (EPS) of NZ$3.19.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60106.89%
2025NZ$3.19
2023NZ-$6.26-62%
2022NZ-$16.4729.03%
2021NZ-$12.76-3.36%
2020NZ-$13.21-8.48%
2019NZ-$14.437.67%
2018NZ-$13.4039.74%
2017NZ-$9.5912.94%
2016NZ-$8.4938.84%
2015NZ-$6.12-32.88%
2014NZ-$9.11259.44%
2013NZ-$2.53-31.25%
2012NZ-$3.69

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.44 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.54-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$75.39 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$14.75-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.29-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.43-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.43-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.62-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA